diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 377f3150e..7a7616275 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -61,22 +61,28 @@ The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (8 ### Additional Evidence (challenge) -*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* +*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16* The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE healthcare costs in elderly populations: muscle loss during treatment + high discontinuation (64.8% at 1 year) + preferential fat regain = sarcopenic obesity → increased fall risk, fractures, disability, and long-term care needs. This directly challenges the Medicare cost-savings thesis by creating NEW healthcare costs (disability, falls, fractures) that may offset cardiovascular and metabolic savings. ### Additional Evidence (extend) -*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16* +*Source: 2025-12-01-who-glp1-global-guidelines-obesity | Added: 2026-03-16* WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing signals institutional uncertainty about durability of outcomes and cost-effectiveness at population scale. WHO requires countries to 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption, suggesting the chronic use economics remain unproven for resource-constrained health systems. ### Additional Evidence (challenge) -*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16* +*Source: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes | Added: 2026-03-16* Danish cohort achieved same weight loss outcomes (16.7% at 64 weeks) using HALF the typical semaglutide dose when paired with digital behavioral support, matching clinical trial results at 50% drug cost. If this half-dose protocol proves generalizable, it could fundamentally alter the inflationary cost trajectory by reducing per-patient drug spending while maintaining efficacy. + +### Additional Evidence (challenge) +*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-16* + +WHO's conditional rather than unconditional recommendation reflects genuine uncertainty about long-term outcomes and cost-effectiveness, with conditionality based on 'limited long-term efficacy/safety data, current high costs, inadequate health-system preparedness, equity implications.' The guideline's announcement of a 2026 prioritization framework for targeting GLP-1 treatment suggests the field is moving toward selective rather than universal use, which would fundamentally alter the cost trajectory assumptions underlying the 'inflationary through 2035' projection. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 518add3b8..02d161e5c 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -55,16 +55,22 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2 ### Additional Evidence (extend) -*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* +*Source: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk | Added: 2026-03-16* The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful. ### Additional Evidence (extend) -*Source: [[2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes]] | Added: 2026-03-16* +*Source: 2025-01-01-jmir-digital-engagement-glp1-weight-loss-outcomes | Added: 2026-03-16* Digital behavioral support may partially solve the persistence problem: UK study showed 11.53% weight loss with engagement vs 8% without at 5 months, suggesting the adherence paradox has a behavioral solution component. However, high withdrawal rates in non-engaged groups suggest this requires active participation, not passive app access. + +### Additional Evidence (extend) +*Source: [[2025-12-01-who-glp1-guidelines-behavioral-therapy-combination]] | Added: 2026-03-16* + +WHO's conditional recommendation requiring behavioral therapy combination suggests the 15% persistence problem may be addressable through standard-of-care adherence support rather than being an inherent limitation of the medication class. The global guideline's emphasis on 'intensive behavioral therapy to maximize and sustain benefits' positions adherence interventions as essential infrastructure, not optional enhancement. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.json b/inbox/archive/.extraction-debug/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.json new file mode 100644 index 000000000..709933ecd --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.json @@ -0,0 +1,26 @@ +{ + "rejected_claims": [ + { + "filename": "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 3, + "rejected": 1, + "fixes_applied": [ + "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md:set_created:2026-03-16", + "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d", + "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category" + ], + "rejections": [ + "who-glp-1-conditional-recommendation-requires-behavioral-therapy-combination-establishing-global-standard.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md b/inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md index 338aa4438..ca707a593 100644 --- a/inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md +++ b/inbox/archive/2025-12-01-who-glp1-guidelines-behavioral-therapy-combination.md @@ -7,9 +7,13 @@ date: 2025-12-01 domain: health secondary_domains: [] format: guideline -status: unprocessed +status: enrichment priority: high tags: [who, glp-1, obesity, guidelines, behavioral-therapy, global-health, equity, access, semaglutide, tirzepatide, liraglutide] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -62,3 +66,12 @@ This is worth a separate archive from the basic WHO announcement because the beh PRIMARY CONNECTION: GLP-1 cost-effectiveness under capitation requires solving the adherence paradox (March 12 claim candidate) WHY ARCHIVED: WHO formal guideline establishing behavioral therapy + GLP-1 as global standard of care — this changes the economic model analysis since behavioral support is now the baseline, not an add-on EXTRACTION HINT: The conditional recommendation structure and the behavioral therapy requirement are the extractable elements. The basic fact of WHO approving GLP-1s is in the existing archive; this archive is specifically about the standard-of-care implications. + + +## Key Facts +- WHO issued first-ever global guidelines on GLP-1 medicines for obesity treatment on December 1, 2025 +- Guidelines cover three agents: liraglutide, semaglutide, tirzepatide +- Recommendations are conditional rather than unconditional +- Conditionality based on: limited long-term efficacy/safety data, current high costs, inadequate health-system preparedness, equity implications +- Guidelines published simultaneously in JAMA +- WHO will develop evidence-based prioritization framework in 2026 to identify which adults with obesity should be prioritized for GLP-1 treatment